Annual report
4564.TEDINET S100YHRD
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 125
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥809m | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥750m | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Operating income | −¥810m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | −¥798m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | −¥846m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥908m | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥813m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥911m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥911m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥2.4bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥867m | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.5bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥2.7bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥217m | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥426m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.1bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥729m | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.0bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥834m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.1bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥834m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.8bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥923m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥795m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥63m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥279,000 | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥33m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥20m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥2.2bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥671m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥96m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-2.77 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.05 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5.4 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2.42 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1.28 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4.04 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥9.84 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 87.8% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 46 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 47 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 54 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 60 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 67 | at 2022-03-31v | Cons. | Number of employees |
| Operating income | −¥769m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | −¥728m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | −¥776m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥712m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥873m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.0bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥909m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥814m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | −¥911m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | −¥815m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥1.0bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.1bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥2.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.3bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥840m | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥507m | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥949m | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.1bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥111m | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥111m | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.1bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥729m | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥575m | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.7bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥614m | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-2.77 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.74 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.8 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.94 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5.4 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2.42 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1.28 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2.58 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥8.38 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 91.9% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.0% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 383,643,700 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 271,643,700 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 217,643,700 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 18 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 18 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 27 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 28 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 36 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥307,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥307,000 |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥170m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥223m |
| Cancer Precision Medical Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥63m |
| Cancer Precision Medical Businessreportable segment | employees | at 2026-03-31 | 28 pure |
| Cancer Precision Medical Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥806m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥806m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2026-03-31 | ¥326m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥56m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2026-03-31 | 18 pure |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥307,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2026-03-31 | ¥2.2bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥532m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥63m |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥809m |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥809m |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥307,000 |
| —segment total | segment assets | at 2026-03-31 | ¥2.5bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | −¥587m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥294,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥294,000 |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥107m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥220m |
| Cancer Precision Medical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥279,000 |
| Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥747m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥747m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2025-03-31 | ¥470m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥91m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥294,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2025-03-31 | ¥792m |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥487m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥279,000 |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥750m |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥750m |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥294,000 |
| —segment total | segment assets | at 2025-03-31 | ¥1.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | −¥578m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2026-03-31 | 18 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,149
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)やまと監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)木村 喬 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)遠坂 匡紀 | |
| Audit opinion consolidated (text) | FilingDateInstant | Text · Plus | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)継続企業の前提に関する重要な不確実性の有無についての経営者による判断の妥当性の評価 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)やまと監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)木村 喬 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)遠坂 匡紀 | |
| Audit opinion non consolidated (text) | FilingDateInstant | Text · Plus | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)継続企業の前提に関する重要な不確実性の有無についての経営者による判断の妥当性の評価 | |
| Same as kam for consolidated fskam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Business revenue (5-year summary) | Prior4YearDuration | 1153663000 | JPY |
| Business revenue (5-year summary) | Prior3YearDuration | 1134903000 | JPY |
| Business revenue (5-year summary) | Prior2YearDuration | 610118000 | JPY |
| Business revenue (5-year summary) | Prior1YearDuration | 750048000 | JPY |
| Business revenue (5-year summary) | CurrentYearDuration | 808530000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | -2071783000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | -1133099000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | -1136373000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | -815046000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | -845811000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | -2571541000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | -1118644000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | -1288138000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | -815285000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | -910638000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | -2571541000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | -1118644000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | -1288138000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | -815285000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | -910638000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 1980233000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant | 855169000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant | 353666000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 729111000 | JPY |
| Net assets (5-year summary) | CurrentYearInstant | 2141980000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant | 2685199000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |